Many of the people most engaged with our poster were already advocates, which may explain why the focus shifted quickly to ...

The study finds that healthcare settings are a leading source of stigma for people living with rare conditions ...

Stop pushing content at a burnt-out audience and start creating "Digital Magnetism." Join Impetus Digital to unlock the 2026 ...

GenAI literacy is not about turning everyone into a technologist. It is about teaching people how to sense-check outputs, recognise bias and know when human judgement must take precedence. In ...

Precision intelligence offers a path forward – pharma-specific, human-led and already in use by teams managing complex, ...

These rules apply to pharma. For distribution, medicine approvals and access are essential. For mental availability, brands ...

Identifying the right specialists with precision data In rare disease, access to treatment starts long before launch. Patient populations are small and dispersed, and the physicians who treat them ...

Under the agreement, Vivtex will license select oral drug-delivery technologies to Novo Nordisk, while Vivtex is eligible to receive upfront consideration, research funding and milestone payments ...

In a deal worth $950m, GSK has agreed to acquire 35Pharma, a private, clinical-stage biopharmaceutical company based in Canada that specialises in the development of novel protein-based therapeutics.

Ethan Mollick’s idea of the ‘jagged frontier’ of AI 1 is one of the most useful ways of describing the problem with the ...

Rare diseases are individually uncommon, yet together they affect an estimated 300 million+ people worldwide and touch the lives of over one billion when ...

As of 1 January 2027, Novo Nordisk will lower the list price, or wholesale acquisition cost, to $675 for Wegovy (semaglutide) ...